This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Platelet derived growth factor receptor B (PDGFRB; PDGFR1; CD140B)

Mouse studies suggest thalidomide could help reduce cardiotoxicity in patients with cancer given Sutent sunitinib. In mice, sunitinib induced cardiotoxicity and microvascular dysfunction. In mice with transverse aortic constriction, sunitinib decreased Pdgfrb expression and pericyte numbers in the microvasculature compared with no treatment. In the same mice, thalidomide decreased sunitinib-induced cardiotoxicity compared with vehicle. Next steps include exploring low-dose thalidomide in combination with various PDGFR inhibitors and understanding the role of pericytes in the heart.
Pfizer Inc. markets the receptor tyrosine kinase (RTK) inhibitor Sutent to treat gastrointestinal stromal tumors (GISTs) and advanced renal cell carcinoma (RCC).
Celgene Corp. markets thalidomide as Thalomid.

SciBX 6(25); doi:10.1038/scibx.2013.621
Published online June 27, 2013

Patent and licensing status undisclosed

Chintalgattu, V. et al. Sci. Transl. Med.; published online May 29, 2013;
doi:10.1126/scitranslmed.3005066
Contact: Aarif Y. Khakoo, Amgen Inc., South San Francisco, Calif.
e-mail:
akhakoo@amgen.com
Contact: Vishnu Chintalgattu,
same affiliation as above
e-mail:
vishnuc@amgen.com